BSX stock news · Boston Scientific Corporation
Get alerts for BSX
Follow Boston Scientific Corporation (BSX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BSXPenumbra, Inc. shares its financial results for the third quarter of 2026.
NeutralThe report says Penumbra's acquisition by Boston Scientific is pending. It gives no new results or deal terms for Boston Scientific, so it does not change the company's outlook.
Today, big investors are making moves with 10 health care stocks.
NeutralBoston Scientific had a put trade labeled bullish. The report gives no new company result or plan, so this trading activity does not change its outlook.
Boston Scientific says some directors are leaving, new ones are joining, and Joe Fitzgerald is now Chief Operating Officer.
NeutralBoston Scientific named longtime executive Joe Fitzgerald as its next chief operating officer and set his pay. His experience may support continuity, but the filing gives no clear reason to change the company's outlook.
Boston Scientific is losing some directors and officers, while also bringing in new ones and changing pay for some leaders.
NeutralBoston Scientific said Arthur Butcher will retire Jan 1, 2027 and serve as senior advisor through Feb 26, 2027; this change reads neutral for BSX.
Big investors are making moves in 10 health care stocks today.
Good for BSXBoston Scientific saw a bullish call sweep; 505 contracts traded at the $47 strike expiring Oct 16, 2026.
Imax could jump over 23%! Check out 10 expert predictions for Wednesday.
Bad for BSXBTIG cut Boston Scientific's price target from $60 to $56 while keeping a Buy, which signals a reduced near-term expectation for Boston Scientific.
Spinal Cord Stimulator Leads recalled by Boston Scientific due to potential fracture hazards.
Bad for BSXBoston Scientific has issued an urgent recall of its Infinion CX Lead, a component of its Spinal Cord Stimulator System, due to a serious risk of lead fractures that could result in severe patient harm or death. The FDA has classified this recall as the most serious type, necessitating immediate action from healthcare providers to withdraw the affected products.